Difference between revisions of "Part:BBa K2669000:Experience"
m |
m |
||
| Line 1: | Line 1: | ||
<html> | <html> | ||
__NOTOC__ | __NOTOC__ | ||
| − | This experience page is provided so that any user may enter their experience using this part.<BR>Please enter | + | <br> |
| − | how you used this part and how it worked out. | + | |
| + | This experience page is provided so that any user may enter their experience using this part. | ||
| + | |||
| + | <BR> | ||
| + | |||
| + | Please enter how you used this part and how it worked out. | ||
===Applications of BBa_K2669000=== | ===Applications of BBa_K2669000=== | ||
Revision as of 11:41, 30 September 2018
__NOTOC__
This experience page is provided so that any user may enter their experience using this part.
Please enter how you used this part and how it worked out.
===Applications of BBa_K2669000===
After transforming our cells with a low copy amplicilin plasmid containing this composite part, cell lysis and affinity chromotography were used to extract UnaG from our cells. Please note: The exact procedure can be found here Bilirubin tests (addition of a small amount of bilirubin to samples) allowed us to see if the UnaG was present in our samples, since as mentioned earlier UnaG fluoresces in the presence of bilirubin.
Figure 2: Bilirubin test before/after affinity chromatography. Going from right to left the samples are:
- Lysed sample of the “bad” part before AC
- Lysed sample of the “good” part before AC
- "Bad" part after AC
- "Good" part after AC